Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Stillitano

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Nature Communications|April 30, 2015
Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapyIoannis Karakikes, Francesca Stillitano, Mathieu Nonnenmacher, et al.
Journal of Personalized Medicine|July 2, 2021
Impaired Right Ventricular Calcium Cycling Is an Early Risk Factor in R14del-Phospholamban ArrhythmiasKobra Haghighi, George Gardner, Elizabeth Vafiadaki, et al.
Cardiovascular Research|February 22, 2022
Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impactJaydev Dave, Nour Raad, Nishka Mittal, et al.
European Heart Journal Open|January 15, 2026
Setting the stage for cardiomyopathy gene editing trials: a systematic review of isogenic pair use in human induced pluripotent stem cell-derived cardiomyocyte researchC Nina van der Wilt, Rogier J A Veltrop, Maaike H Janssens, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Nature Communications|April 30, 2015
Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapyIoannis Karakikes, Francesca Stillitano, Mathieu Nonnenmacher, et al.
Journal of Personalized Medicine|July 2, 2021
Impaired Right Ventricular Calcium Cycling Is an Early Risk Factor in R14del-Phospholamban ArrhythmiasKobra Haghighi, George Gardner, Elizabeth Vafiadaki, et al.
Cardiovascular Research|February 22, 2022
Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impactJaydev Dave, Nour Raad, Nishka Mittal, et al.
European Heart Journal Open|January 15, 2026
Setting the stage for cardiomyopathy gene editing trials: a systematic review of isogenic pair use in human induced pluripotent stem cell-derived cardiomyocyte researchC Nina van der Wilt, Rogier J A Veltrop, Maaike H Janssens, et al.
Pageof 5